Advances in use of the 5-HT3 receptor antagonists

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 2, 2000, Pages 207-223

  Walton, Suzanne M ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

5 HT3 antagonists; Anti emetics; Dolasetron; Granisetron; Ondansetron

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; SEROTONIN 3 RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG EFFECT; HUMAN; REVIEW; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS; VOMITING;

EID: 0033755069     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.2.207     Document Type: Article

References (108)

1. COAXES A, ABRAHAM S, KAYE SB et at.: On the receiving end-patient perception of the side-effects of cancer chemotherapy. Etir.J. Cancer(l985) 19:203-208.
2. 3 antagonists. Br.J. Cancer (.lyn') 76(8):1055-106l.
3. LASZLO J, LUCAS VS: Eniesis as a critical problem in chemotherapy. A'. Engl.J. Meet. (1981) 305:948-949.
4. OSOBA D, ZEE B, PATER J, \VARR D, LATREILLE J, KAIZER L: Determinants of postchemotherapy nausea and vomiting in patients with cancer./ Clin. Oncol. (1997) 15:116-123.
5. GUILLEM V. AKANDA E. CARRATO A ct a!.: Previous history of emcsis during pregnancy and motion sickness as risk factors for chemotherapy-induced emcsis. /'roc. AStCH 1999) 18:590a. Abstract 2280.
6. CUKEDDU LX: Mechanisms by which cancer chemothcrapeutic drugs induce emcsis. Si'iiiin. Oncol. (1992) 19:2-13. Review of the pathogenesis of chemotherapy-induced nausea and vomiting including the role of serotonin.
7. SEIGEL LJ. LONGO DL: The control of chemotherapy-induced emcsis. Ann. Intern.. \Ietl. (1981) 95:352-3 59. Review of the physiology of chemotherapy-induced nausea and vomiting and the agents commonly used at the writing of the article.
8. ETTINGEK DS: Preventing chemotherapy-induced nausea and vomiting: an update and a review of emcsis. Scmiii. Unco!. (1995) 4:6-18. Review of the pathophysiology, risk factors and treatment of chemotherapy-induced nausea and vomiting.
9. 3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting: a comparison of their pharmacology and clinical efficacy. Dmgs (1998) 55:173-189.
10. CUBEDDU LX. HOFFMANN IS, FUENMAYOK NT, FINN AL:. Efficacy of ondansctron (GR 38032F) and the role of scrotonin in cisplatin-induccd nausea and vomiting.A'. Engl.J. Mal. (1990) 322:810-816.
11. MART M. POUILLART P, SCHOLL S étal.-. Comparison of the 5-hydroxytryptaminc3 (serotonin) antagonist ondansctron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induccd emesis. A'. Engl.J. Mi-el. (1990) 322:816-821.
12. HAINSWORTH J. HARVEY \V, PENDERGRASS K ct ah. A single-blind comparison of intravenous ondansetron, a selective scrotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy..J. Clin. Oncol. (1991) 9:721-728.
13. DEMULDER I'HM. SEYNAEVE C, VERMORKEN JB el al: Ondansctron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induccd nausea and vomiting. Ann. Intern. Meet. (1990) 113:834-840.
14. BECK TM, CIOCIOLA AA, JONES SE et eil.: Efficacy of oral ondansctron in the prevention of emcsis in outpatients receiving cyclophosphamidc-bascd chemotherapy. Ann. Intern. Meel. (1993) 118:407-413.
15. LEVITT M, \VARR D, YELLE L et ell.: Ondansetron compared with dcxamethasonc and metoclopramide as anticmctics in the chemotherapy of breast cancer with cyclophosphamidc, methotrcxatc, and fiuorouraciL A'. Engl.J. Meil. (1993) 328:1081-1084.
16. HERRSTEDTJ, SIGSGAARD T, BOESGAARD M, JENSEN TP, DOMBERNOWSKY P: Ondansetron plus metopimazine compared with ondansctron alone in patients receiving moderately emctogcnic chemotherapy. A'. Engl.J. Med. (1993) 328:1076-1080.
17. BREGNI M, SIENA S, DIN1COLA M. BONADONNA G. GIANNI AM:. Tropisetron plus halopcridol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy. Enr. J. Cancer (1991) 27:561-565. Evidence-based recommendations for anti-emetic usage for chemotherapy-and radiation-induced emesis from the American Society of Clinical Oncology.
18. ROILA F, TON'ATO M, COGNETTI F et ill.: Prevention of cisplatin-induced cmcsis: a double-blind multicenter randomized crossover study comparing ondansctron and ondansctron plus dcxamcthasonc. J. Clin. Oncol. (1991)9:675-678.
19. SHTH JF, COLEMAN KE. NICOLSON M et til.: Does dcxamcthasonc enhance control of acute cisplatin induced cmesis by ondansetron? Kr. Meet. J. (1991) 303:1423-1-426.
20. SMITH DU, NEWLANDS ES, KUSTIN GJS et ill.: Comparison of ondansctron and ondansetron plus dcxamcthasonc as anticmetic prophylaxis during cisplatin-containing chemotherapy. Lancet (1991) 338:487-490.
21. JOSS RA, liACCHI M, HUSEK K et al.: Ondansetron plus dcxamcthasone is superior to ondansetron alone in the prevention of cmcsis in chemotherapy-naive and previously treated patients. Ann. Oncol. (1994) 5:253-258.
22. KRIS MG, GRALLA RJ, CLARK RA et ill.: Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. J\CI( 1989) 81:42-46.
23. HESKETH PJ. MURPHY \VK, LESTER EP et al.: GR38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis. J. Clin. Oncol. (1989) 7:700-705.
24. BECK TM, HESKETH PJ, MADAJEWICZ S et a!.-. Stratified, randomized, double-blind comparison of intravenous ondansctron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J. Clin. Oncol. (1992) 10:1969-1975.
25. SEYNAEVE C, SCHULLERJ, BUSEK K étal: Comparison of the anti-emetic activity of different doses of ondansctron, given as cither a continuous infusion or a single intravenous dose, in acute cisplatin-induccd cmcsis. A multiccntrc, double-blind, randomised, parallel group study. Br.J. Cancer (.1992) 66:192-197.
26. SYLVESTER RK. ETZELL P, LEV1TT R et al.: Comparison of 16 nigrs. 32 mg ondansctron and dcxamcthasone in patients receiving cisplatin. ['me. ASCO (1996) 15:547. Abstract 1781.
27. PECTASIDES D, MYLONAKIS A, VARTHALITIS J et al.-. Comparison of two different doses of ondansetron plus dcxamethasonc in the prophylaxis of cisplatin-induccd cmcsis. Oncology (1997) 54:1-6.
28. ROILA F. BALLATORI E, DEANGELIS V, TONATO M, DEL FAVERO A: Double-blind, dose-finding study of four intravenous doses of dcxamcthasonc in the prevention of cisplatin-induced acute cmcsis. / Clin. Oiiail. (1998) 16:2937-2942.
29. TYSON LB, KRIS MG. BALTZER L et al.: Randomized Phase II trial comparing two versus three doses of ondansctron when used with dcxamcthasonc in patients receiving cisplatin > 100 mg/m2. Ani.J. Gin. Oncol. (1994) 17:269-272.
30. ASHP therapeutic guidelines on the pharmacologie management of nausea and vomiting in adult and pédiatrie patients receiving chemotherapy or radiation therapy or undergoing surgery. Am. J. ccilth-Syst. I'bcmn. (1999) 56:729-764. Guidelines for the use of anti-emetics for the prevention of both chemotherapy- and radiation-induced as well as post-operative nausea and vomiting.
31. National Comprehensive Cancer Network (NCCN) aiiticnicsis practice guidelines. Oncology- (1997) 11:57-89. Guidelines for the use of anti-emetics for the prevention of chemotherapy- and radiation-induced nausea and vomiting.
32. HESKETH PJ. BECK TM, UHLENHOPP M et ill.: Adjusting the dose of intravenous ondansetron plus dcxamcthasonc to the emetogenic potential of the chemotherapy regimen./ Clin. Oncol. (1995) 13:2117-2122.
33. DIPIRO CV, SANAL SM, HARKNESS KT ft ell.: The anticmctic efficacy of intravenous ondansetron (OND) at conventional versus low dose in women with early stage breast cancer, five. ASCO (1996) 15:540. Abstract 1752.
34. KAIZER L, WARR D, HOSKINS P ft a!.: Effect of schedule and maintenance on the anticmctic efficacy of ondansctron combined with dexamcthasonc in acute and delayed nausea and cmcsis in patients receiving moderately emetogenic chemotherapy: a Phase III trial by the National Cancer Institute of Canada clinical trials group./ Clin. Oncol. (1994) 12:1050-1057.
35. GEBBIA V, CANNATA G, TESTA A et al.: Ondansctron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer (1994) 74(7,1:1945-1948.
36. MARKMAN M, KENNEDY A, WEBSTER K ft ai: Low-dose intravenous ondansctron (8 mg) plus dcxamcthasonc: an effective regimen for the control of carboplatin-induccd cmcsis. / Cancer Res. Clin. Oncol. (1997)123:224-226.
37. BONNETERRE J, HECQUET B: Granisetron IV compared with ondansctron IV plus Tablets in the prevention of nausea and vomiting induced by a moderately emetogenic chemotherapy regimen: a randomized cross-over study. European Conference on Clinical Oncolog): Jerusalem, Israel (14 November 1993).
38. 3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy - a randomized study. Eur. J. Cancer (1993) 29A:1669-1672.
39. 3-receptor-antagonist in moderately cmetogenic chemotherapy. J. Cbemotber. (1996)8(3>:237-242.
40. Glaxo Wellcome. Inc. Zofrnn package insert. Research Triangle Park. NC. USA (January 1999).
41. KRZAKOWSKI M. GRAHAM E. GOEDHALS L et ai: A multicentcr, double-blind comparison of i.v. and oral administration of ondansctroii plus dcxamcthasonc for acute cisplatin-induccd emesis. AnttCancer Drugs (1998)9:593-598.
42. LINDLEY C, MCCUNE J. GOODIN S et al.: Efficacy of oral ondansetron and dcxamcthasonc in prevention of nausea and vomiting associated with moderately-high and highly cmetogenic chemotherapy, five. ASCO (1998) 17:63a. Abstract 244.
43. SPECTOR JI. LESTER EP. CHEVLON E\l: A comparison of oral ondansetron and intravenous granisctron for the prevention of nausea and emesis associated with cisplatin-bascd chemotherapy. Oncologist (1998) 3:432-438.
44. FRANCHI M, DONADELLO N, ZANABONI F et fil.: Oral ondansctron and intravenous dcxamcthasonc in the prevention of cisplatin-induccd emesis. Oncology (1995) 52:509-512. .
45. SMITH DB. NEWLANDS ES, KUSTIN GJS et ill.: Comparison of ondansctron and ondansctron plus dcxamcthasonc as anticmetic prophylaxis during cisplatin-containing chemotherapy. Lancet (1991) 338:487-490.
46. YILMAZ UM, UTKANER G, YUKEL M et a!.: Ondansetron Tablet plus dexamethasone in the prophylaxis of acute emesis and nausea associated with low or high dose cisplatin-based chemotherapy in lung cancer: a double-blind comparative, consecutive study, lung Cancer (1997) 18(Suppl. 1):211. Abstract 819.
47. CAMPOKA E, CHIARA S, ASCHELE C: Ondansetron for the control of dacarbazinc-induccd emesis. Etir. J. Grir(1995)31A(10):1720-1721.
48. BOSNJAK SM, NESKOVIC-KONSTANTINOVIC ZB, JOVANOVIC-MICIC DJ, MITROVIC LB, RADULOVIC SS: Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting./ Cbemotber. (1996) 8.315-318.
49. CARMICHAEL J, CANTWELL BMJ, RAI'PEPORT \VG et dl.: BRL 43694A, a selective 5-HTs receptor antagonist: a dose-ranging study for control of cisplatin-induccd emesis. Br.J. Cancer (1988) 58:266.
50. CASSIDY J, LEWIS C, RAPEPORT WG et al.-. Antiemetic activity of BRL 43694A, a selective 5-HTs receptor antagonist in cancer chemotherapy. Br.J. Cancer(.l9S8) 58:275.
51. GUMBRELL LA, QUALMAN C, PERREN TJ: An open pilot study of the 5-HI3 antagonist BRL43694A, an effective anticmetic in refractory highly emetogcnic cytotoxic drug induced emesis. Br.J. CancerdVSS) 58:274-275.
52. SOUKOP M, GRANISETKON STUDY GROUP: A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. Eur.J. Cflwer (1990) 26 (Suppl. 1):S15-S19.
53. KA.MANAHKOU D, GRANISETRON STUDY GROUP: Intravenous granisetron - establishing the optimal dose. Eur.J. Cancer(1992) 28A(Suppl. 1):S6-S11.
54. NAVARI RM, I'LEZIA P, KAPLAN HG, GRALLA RJ, GRUNBEKG SM: Single-dose, double-blind multiccnter study evaluating the efficacy and safety of intravenous (IV) granisctron in the prevention of cisplatin-induced nausea and vomiting, five. ASCOW9}) 12:438. Abstract 1511.
55. ABBOTT B, IPPOLITIC, BRUTON J, NEUMANN. J. WHALEY R. CHAMPLIN R: Anticmctic efficacy of granisetron plus dcxamethasonc in bone marrow transplant patients receiving chemotherapy and total body irradiation. littne Murrow Transplant. (1999) 23:265-269.
56. SmithKline Beecham Pharmaceuticals. K>tril package insert. Philadelphia, PA, USA (April 1999).
57. ABANG AM, TAKEMOTO MM, PHA.M T et al.: A randomized, double-blind, pilot study comparing the efficacy and safety of oral granisetron to intravenous granisctron in patients undergoing peripheral blood stem cell and bone marrow transplantation, /'roc. ASCO(1998) 17:52a. Abstract 200.
58. HALL PD, FREILAHR D, STUART RK: A Phase HI trial of granisctron for prevention of nausea and vomiting in patients receiving high-dose cyclophosphamidc regimens followed by stem cell transplantation. Bluod (1996) 88 (Suppl. l):415a. Abstract 1650.
59. FRAKES LA, BREH.M TL. KOSTY MP et al.: An all oral anticmetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stem cell transplant. Bone Marivw Transplant. (1997) 20:-473-478.
60. BLEIBERG HH. SPIELMANN M, FALKSON G. ROMAIN D et al.-. Antiemetic treatment with oral granisetron in patients receiving moderately cmetogcnic chemotherapy: a dose-ranging study. Clin. TJ.ier. (1995) 17:38-51.
61. MARKMAN M, KENNEDY A, WEBSTER K, KULP B, PETERSON G, BELINSON J: Low-dose oral granisetron (1 mg) plus intravenous dcxamethasonc: efficacy in gynecologic cancer patients receiving carboplatin-bascd chemotherapy. Gynecol. Oncol. (1998)71:113-115.
62. HERON JF, GOEDHALS L, JORDAAN JP, CUNNINGHAM J, CEDAR E: Oral granisctron alone and in combination with dcxamethasonc: a double-blind randomized comparison against high-dose mctoclopramidc plus dcxamethasonc in prevention of cisplatin-induced emesis. Ann. Oncol. (1994) 5:579-584.
63. HESKETH PJ, CKEVi'S JR, COHEN R, BLACKBURN LM, FRIEDMAN CJ: Efficacy of a single 1-mg or 2-mg dose of oral granisctron for the prevention of nausea and vomiting induced by IV cyclophosphamidc- or carboplatin-bascd chemotherapy regimens. Proc. SCO(1999) 18:593a. Abstract 2290.
64. THANT M, PENDERGRASS K, HARMAN G et dl.: Double-blind, randomized study of the dose-response relationship across five single doses of IV dolasctron mesylatc for prevention of acute nausea and vomiting after cisplatin chemotherapy. I'roc. ASC.O ( 1996) 15:533. Abstract 1727.
65. BERTOLI L, YEILDING A. HANKINS J el J.: Antiemetic dose finding study of a specific 5-hydroxytryptamine (5HTs) receptor antagonist (MDL 73, 147EF) in patients receiving high dose cisplatin chemotherapy. I'roc. ASCOW92) 11:395. Abstract 1377.
66. CLARK KA, GRALLA RJ, GRUNBERG S.\l. KRIS MG, HAHNE \VF: Effective single dose anticmctic treatment in patients receiving high cisplatin doses: establishment of the optimal IV dose of the 5-HTs antagonist MDL 73, 147EF. Pmc. ASCOt 1992) 11:382. Abstract 1325.
67. KASIMIS 15, TAPAZOGLOU E. SCHULMAN 1' et cil.: A double-blind, randomized study of two different dose regimens of intravenous dolasctron in patients receiving high dose cisplatin chemotherapy. Pmc. AÄXK1994) 13:446. Abstract 1538.
68. KRIS MG, GRUNI5ERG SM, GRALLA RJ etui: Dose-ranging evaluation of the scrotonin antagonist dolasctron mesylate in patients receiving high-dose cisplatin. J. Clin. Oncol. (1994) 12:1045-1049.
69. HARMAN GS, OMURA GA, RYAN K, HAINSWORTH JD, CRAMER MB, HAHNE VC'F: A randomized, double-blind comparison of single-dose and divided multiple-dose dolasctron for cisplatin-induccd cmcsis. Cancer Cbemotber. Pbarmacol. (1996) 38:323-328.
70. WHITMOREJB, KRIS MG. HESKETH PJ etal.: Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induccd nausea and vomiting. Support Canr Cancer (.1998) 6:473178.
71. Hoechst Marion Roussel, Inc. Anzemet package insert. Kansas City, MO, USA (October 1997,1.
72. RUBENSTEIN EB, GRALLA RJ, HAINSWORTH JD et al.: Randomized, double blind, dose-response trial across four oral doses of dolasctron for the prevention of acute cmesis after moderately emetogenic chemotherapy. Cancer (1997) 79:1216-1224.
73. GROTE TJ, PINEDA LF, FIGLIN RA et al.: Oral dolasetron mesylatc in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral dolasetron dose response study group. Cancer J. Sei. Am. (1997) 3:45-51.
74. FAUSER AA, DUCLOS B, CHEMAISSANI A et al.: Therapeutic equivalence of single oral doses of dolasctron mcsilatc and multiple doses of ondansctron for the prevention of emesis after moderately emetogenic chemotherapy. Etir. J. Cancer (1996) 32:1523-1529.
75. FAUSER A, BLEIBERG H, CHEVALLIER B et al.: A double-blind randomized comparative trial of IV dolasctron vs. IV metoclopramide in prevention of emesis in moderatcly-emetogcnic chemotherapy. Pmc. ASCOW95) 14:530. Abstract 1748.
76. AUDHUY I!. CAPPELAEKE P, MARTIN M et ill.: A double-blind, randomised comparison of the anticmctic efficacy of two intravenous doses of dolasetron mesilate anil granisetron in patients receiving high dose cisplatin chemotherapy. Enr. J. C<7;;r(1996) 32A:807-813-
77. GEBBIA V, CANNATA G. TESTA A et eil.: Ondansctron rersus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer (1994) 74:1945-1952.
78. ITALIAN GROUP FOR ANTIEMETIC RESEARCH: Ondansctron versus granisetron, both combined with dcxamcthasone, in the prevention of cisplatin-induccdcmcsis. Ann. Oncol.( 1995)6:805-810.
79. MÄNTOVANI G, MACCIO A. BIANCHI A ('/ ell.: Comparison of granisetron, Ondansctron, and tropisctron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. CcinceK 1996) 77:94 1 -9-48.
80. MARTONI A, ANGELELLI B, GUARALDI E t't at.: An open randomised cross-over study on granisetron versus ondansctron in the prevention of acute emcsis induced by moderate dose cisplatin-containing regimens. Enr.J. Cancer W96) 32A:82-85.
81. MARTY M, KLEISBAUER J-P. FOURNEL P et al.-. Is Novoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induccd emesis? AntiCeincer Drugs (1995) 6:15-21.
82. HESKETH P, NAVARI R, GROTE T el ell.: Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansctron in the prevention of acute cisplatin-induccd emesis in patients with cancer. / Clin. Oncol. (1996) 14:2242-2249.
83. NOBLE A. BREMERK, GÖEDHALS Létal.-. A double-blind, randomized, crossover comparison of granisetron and ondansctron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference Etir. J. trans (1994) 30A:1083-1088.
84. RUFF P..PASKA \V, GÖEDHALS L et ell.: Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute cmcsis: a multiccntrc double-blind, randomised, parallel-group study. Oncology (1994) 51:113-118.
85. GRALLA RJ, NAVARI RM, HESKETH PJ et cil.: Single-dose oral granisetron has equivalent anticmctic efficacy to intravenous ondansctron for highly emetogenic cisplatin-bascd chemotherapy. / Clin. Oncol. (1998) 16:1568-1573.
86. NAVARI R. GANDARA D, HESKETH P et eil.: Comparative clinical trial of granisetron and ondansctron in the prophylaxis of cisplatin-induccd emesis./ Clin. Oncol. (1995) 13:1242-1248.
87. BONNETERRE J, HECQUET B, FRENCH NORTHERN ONCOLOGY GROUP: Granisetron (iv) compared with ondansctron (iv plus oral) in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a cross-over study. Bull. Cancer (1995) 82:1038-1043.
88. CAMPORA E. SIMON! C. KOSSO R: TropLsetron versus ondansetron nclla prevenzione e controllo dcll'emesi in pazicnti sotto-poste a chcmiotcrapia con FAC/FEC per carcinoma mammario metastatico o operato. Mincira Meilica (1990 85:25-31.
89. 3 receptor antagonists in the propliylaxis of acute vomiting induced by moderately emetogenic chemotherapy - a randomised study. Ear. J. Cancer (1993) 29A:1669-1672.
90. JANTUNEN IT, KATAJA VV. JOHANSSON RT: Ondansetron and tropisctron with dcxamcthasone in the prophylaxis of acute vomiting induced by non-cisplatin-containing chemotherapy. Acta Oncol. (1992) 31:573-575.
91. LOFTERS NX'S, ZEE I!: Dolasetron vs. ondansetron with and without dcxamcthasonc in the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Support Care Cancer (1995) 3:338.
92. 3 receptor antagonists in chemotherapy induced emesis. Support Care Cancer (1995) 3:340.
93. 3 receptors. Ann. Oncol. (1994) 5(Suppl. 8).204.
94. MERCIER A, KERI3RAT P, ÜLEUSE JI', THE FRENCH GRANISETKON STUDY GROUP: Granisetron/jer os day 1 followed by metocloprâmide po (02-3) compared with ondansetron iv DI and ondansetron po D2-3 in the prevention of nausea and vomiting induced by a moderately emetogenic chemotherapy. Sixth Inlemational Congress on A ntiCcincer Treatment. Paris, France (6-9 Februar)' 1996) 90.
95. PEREZ EA, LEMBERSKY 13, KAYWIN, KALMAN L, YOCUM K, FRIEDMAN C: Comparable safety and anticmctic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minutc) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy. Cancer J. Sei. Am. (199S) 4:52-58.
96. PIONJM, FOURNIERC, DARLOY F < J.: Oral granisetron t'S. oral ondansetron, a comparative double-blind cross-over multicentcr study of preventive anti-emetic in moderately emetogenic chemotherapy, by the French Northern Oncology Group (FNOG). Pmc. ASCO (1996) 15:530. Abstract 1715.
97. SPINA M, VALENTINI M, FEDELE P et al.: Randomized comparison of granisetron vs. ondansctron in patients with HIV-related non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy. Pmc. A$ro(1995) 14:532. Abstract 1757.
98. STEWART A, MCQUADE B, CRONJE JDE et al.: Ondansctron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a niulticcntrc, double-blind, double-dummy, randomised, parallel group study. Oncology (1995) 52:202-210.
99. PEKEZ EA. HESKETH P, SANDBACH .1 et al.: Comparison of single-dose oral granisctron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emctogcnic chemotherapy: a multicentcr, double-blind, randomized parallel study./ Clin. Oncol. (1998; 16:75-1-760.
100. KALAYCIO M, MENDEZ Z. POHLMAN 13 et n!.: Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy. .J. Cancer Res. Clin. Oncol. (1998) 124:265-269.
101. FOX-GEIMAN M. FISHER SG. KILEY K étal.: Double-blind randomized comparison of oral granisctron, oral ondansetron and iv ondansetron for regimen-related nausea and vomiting in patients undergoing stem cell transplants. I'mc. ASCO( 1999) 18:592a. Abstract 2288.
102. YALCIN S, TEKUZMAN G, HALTALI E, OZISIK Y, I3ARISTA I: Scrotonin receptor antagonists in prophylaxis of acute and delayed cmcsis induced by moderately emetogenic, single-day chemotherapy. Am. J. Clin. Oncol. (1999) 22:94-96.
103. ANTIEMETIC SUBCOMMITTEE OF THE MULTINATIONAL ASSOCIATEION OF SUPPORTIVE CARE IN CANCER (MASCO: Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann. Oncol. (1998) 9:811-819-Recommendations for the prevention of chemotherapy- and radiation-induced nausea and vomiting are presented as the result of a consensus conference on anti-emetic therapy.
104. KOLTE MJ, BERKEKY R. 1'IZZO B et al.-. Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional anticmctic guidelines at Memorial Sloan-Kettering Cancer Center. .J. Clin. Oncol. (1998) 16:771-778. A description of the process by which anti-emetic guidelines were developed, implemented, assessed and modified at Memorial Sloan-Kettering Cancer Center.
105. HESKETH I'J. KRIS M. GRUNHERG SM et al.: Proposal for classifying the acute cmctogenicity of cancer chemotherapy. J. dm. Oncol. (1997; 15:103-109. A proposed classification schema for determining the emetogenic potential of various chemotherapeutic agents.
106. 3 receptor antagonists with recommendations on the dose, schedule and route of administration for the prevention of nausea and vomiting due to highly emelogenic chemotherapy.
107. GKALLA RJ, OSOBA D, KRIS MG etal: Recommendations for the use of antiemetics: evidence based, clinical practices guidelines./ Clin. O;;coJ.(1999) 17:2971-2994.
108. Data on file. SmithKIine Beecham Pharmaceuticals. Kytril package insert. Philadelphia, PA, USA (April 1999). Suzanne M Walton Oncology Pharmacy Services, Emory University Hospital, 1364 Clifton Road, NE. Atlanta, GA 30322. USA